1.47
price down icon4.55%   -0.07
after-market Dopo l'orario di chiusura: 1.38 -0.09 -6.12%
loading
Precedente Chiudi:
$1.54
Aprire:
$1.43
Volume 24 ore:
161.88K
Relative Volume:
0.11
Capitalizzazione di mercato:
$949.40K
Reddito:
$644.60K
Utile/perdita netta:
$-9.87M
Rapporto P/E:
-0.00175
EPS:
-837.9618
Flusso di cassa netto:
$-9.02M
1 W Prestazione:
+13.95%
1M Prestazione:
-50.17%
6M Prestazione:
-75.53%
1 anno Prestazione:
-94.65%
Intervallo 1D:
Value
$1.3301
$1.49
Intervallo di 1 settimana:
Value
$1.14
$1.68
Portata 52W:
Value
$1.14
$74.00

Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Company Profile

Name
Nome
Biodexa Pharmaceuticals Plc Adr
Name
Telefono
-
Name
Indirizzo
-
Name
Dipendente
16
Name
Cinguettio
Name
Prossima data di guadagno
2024-06-13
Name
Ultimi documenti SEC
Name
BDRX's Discussions on Twitter

Confronta BDRX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
BDRX
Biodexa Pharmaceuticals Plc Adr
1.47 949.40K 644.60K -9.87M -9.02M -837.96
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.01 125.55B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.64 67.78B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
590.06 36.24B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
262.16 33.99B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
264.32 28.77B 3.81B -644.79M -669.77M -6.24

Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-02-08 Iniziato Ladenburg Thalmann Buy

Biodexa Pharmaceuticals Plc Adr Borsa (BDRX) Ultime notizie

pulisher
Mar 19, 2025

Biodexa Pharmaceuticals advances FAP treatment trial By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

Biodexa Pharmaceuticals advances FAP treatment trial - Investing.com India

Mar 19, 2025
pulisher
Mar 19, 2025

With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter - Barchart.com

Mar 19, 2025
pulisher
Mar 10, 2025

Biodexa gets FDA nod for Phase 3 eRapa study in FAP - Investing.com India

Mar 10, 2025
pulisher
Mar 10, 2025

BDRXBiodexa Pharmaceuticals plc Latest Stock News & Market Updates - StockTitan

Mar 10, 2025
pulisher
Mar 06, 2025

Biodexa selects Precision as CRO for eRapa Phase 3 study in Europe - Investing.com

Mar 06, 2025
pulisher
Feb 12, 2025

Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status - Barchart

Feb 12, 2025
pulisher
Feb 11, 2025

Biodexa Pharmaceuticals Plc ADR [BDRX] Is Currently 31.94 above its 200 Period Moving Avg: What Does This Mean? - The DBT News

Feb 11, 2025
pulisher
Feb 10, 2025

why Teva- Pharmaceutical Industries Ltd. ADR [TEVA] is a Good Choice for Investors After New Price Target of $24.71 - The DBT News

Feb 10, 2025
pulisher
Feb 10, 2025

Palantir Technologies Inc [PLTR] Is Currently -0.39 below its 200 Period Moving Avg: What Does This Mean? - The DBT News

Feb 10, 2025
pulisher
Feb 10, 2025

Biodexa Pharmaceuticals Plc ADR (BDRX) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle

Feb 10, 2025
pulisher
Feb 10, 2025

Hesai Group ADR (HSAI) Shares Up Despite Recent Market Volatility - The News Heater

Feb 10, 2025
pulisher
Feb 10, 2025

Biodexa Pharmaceuticals Plc ADR (BDRX) vs. Its Peers: A Comparison - The News Heater

Feb 10, 2025
pulisher
Feb 10, 2025

Omega Therapeutics Inc (OMGA) Stock: A SWOT Analysis - The News Heater

Feb 10, 2025
pulisher
Feb 10, 2025

AES Corp (AES) Shares Down Despite Recent Market Volatility - The News Heater

Feb 10, 2025
pulisher
Feb 10, 2025

Altus Power Inc (AMPS) vs. Its Peers: A Comparison - The News Heater

Feb 10, 2025
pulisher
Jan 30, 2025

Skechers (SKX) Earnings Expected to Grow: Should You Buy? - Yahoo Finance

Jan 30, 2025
pulisher
Jan 30, 2025

Is Argenx (ARGX) Outperforming Other Medical Stocks This Year? - Yahoo Finance

Jan 30, 2025
pulisher
Jan 14, 2025

Are Medical Stocks Lagging Argenx (ARGX) This Year? - Yahoo Finance

Jan 14, 2025
pulisher
Jan 03, 2025

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Moves to Buy: Rationale Behind the Upgrade - MSN

Jan 03, 2025
pulisher
Dec 29, 2024

European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading - MSN

Dec 29, 2024
pulisher
Nov 28, 2024

Biodexa Pharmaceuticals Plc ADR (BDRX): A New Perspective - Stocks Register

Nov 28, 2024
pulisher
Nov 22, 2024

Result of General Meeting - Yahoo Finance

Nov 22, 2024
pulisher
Nov 21, 2024

Gaining Momentum, Biodexa Is Advancing Two Recent Acquisitions Through The Clinic - Barchart

Nov 21, 2024
pulisher
Nov 12, 2024

Biodexa Pharmaceuticals regains Nasdaq compliance - Investing.com

Nov 12, 2024
pulisher
Nov 07, 2024

Notice of General Meeting - StockTitan

Nov 07, 2024
pulisher
Nov 01, 2024

Biodexa Pharmaceuticals Submits SEC Filing with Auditors’ Nod - TipRanks

Nov 01, 2024
pulisher
Oct 29, 2024

BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the Firm - GlobeNewswire Inc.

Oct 29, 2024
pulisher
Oct 17, 2024

Biodexa reports promising glioblastoma trial results - Investing.com

Oct 17, 2024
pulisher
Oct 17, 2024

Biodexa Pharmaceuticals releases patient updates on PFS, OS from MAGIC-1 study - TipRanks

Oct 17, 2024
pulisher
Oct 17, 2024

Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer - StockTitan

Oct 17, 2024
pulisher
Oct 16, 2024

Stock Surge: Biodexa Pharmaceuticals Plc ADR (BDRX) Closes at 5.01, Marking a -4.21 Increase/Decrease - The Dwinnex

Oct 16, 2024
pulisher
Oct 15, 2024

Biodexa Pharmaceuticals Secures Nasdaq Compliance Extension - TipRanks

Oct 15, 2024
pulisher
Oct 15, 2024

Biodexa secures Nasdaq listing extension - Investing.com

Oct 15, 2024
pulisher
Oct 15, 2024

Biodexa Pharmaceuticals granted extension to regain compliance with Nasdaq - TipRanks

Oct 15, 2024
pulisher
Oct 15, 2024

Biodexa secures Nasdaq listing extension By Investing.com - Investing.com UK

Oct 15, 2024
pulisher
Oct 15, 2024

Biodexa Announces Successful Appeal of Nasdaq Delisting - StockTitan

Oct 15, 2024
pulisher
Oct 05, 2024

Biodexa provides update on PFS, OS in Phase 1 study of MTX110 in rGBM - TipRanks

Oct 05, 2024
pulisher
Oct 04, 2024

Biodexa reports survival rates in glioblastoma study - Investing.com India

Oct 04, 2024
pulisher
Oct 04, 2024

Biodexa reports updated Phase 1 data from glioblastoma study (NASDAQ:BDRX) - Seeking Alpha

Oct 04, 2024
pulisher
Oct 04, 2024

Biodexa’s MTX110 Shows Promise in Brain Cancer Study - TipRanks

Oct 04, 2024
pulisher
Oct 04, 2024

Biodexa reports survival rates in glioblastoma study By Investing.com - Investing.com UK

Oct 04, 2024
pulisher
Oct 04, 2024

Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma - StockTitan

Oct 04, 2024
pulisher
Sep 26, 2024

Should investors be concerned about BDRX’s high price-to-sales ratio? - US Post News

Sep 26, 2024
pulisher
Sep 26, 2024

Interim results for the six months ended June 30, 2024 - StockTitan

Sep 26, 2024
pulisher
Sep 19, 2024

Biodexa Pharmaceuticals Announces ADR Ratio Change - TipRanks

Sep 19, 2024
pulisher
Sep 19, 2024

ADR Ratio Change - GlobeNewswire

Sep 19, 2024
pulisher
Sep 19, 2024

Biodexa Pharmaceuticals announces ADR ratio change - Investing.com

Sep 19, 2024
pulisher
Sep 16, 2024

Biodexa secures full access to cancer research grant - Investing.com

Sep 16, 2024
pulisher
Sep 02, 2024

Biodexa Pharmaceuticals Plc ADR (BDRX) produces promising results - US Post News

Sep 02, 2024
pulisher
Aug 30, 2024

Receipt of Nasdaq Delisting DeterminationPlans to Appeal - StockTitan

Aug 30, 2024

Biodexa Pharmaceuticals Plc Adr Azioni (BDRX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$67.48
price down icon 1.23%
$73.33
price down icon 0.15%
$31.79
price up icon 1.63%
$18.91
price down icon 7.58%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 3.81%
Capitalizzazione:     |  Volume (24 ore):